Xenon Pharmaceuticals Inc. (FRA:XP0)

Market Cap	2.77B -5.7%
Revenue (ttm)	6.39M
Net Income	-261.09M
EPS	-3.31
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8
Open	36.40
Previous Close	35.80
Day's Range	36.40 - 36.40
52-Week Range	25.00 - 39.00
Beta	n/a
RSI	57.92
Earnings Date	Feb 27, 2026

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The com...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 322
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: XP0

Financial Performance

Financial numbers in USD